Ignite Creation Date:
2024-05-06 @ 12:17 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01535989
Status:
COMPLETED
Last Update Posted:
2016-06-07
First Post:
2012-01-27
Brief Title:
Study of Inotuzumab Ozogamicin Temsirolimus in Patients With Relapsed or Refractory CD22 B-cell NHLymphoma
Sponsor:
Cristiana Sessa
Organization:
Oncology Institute of Southern Switzerland
Organization Data
Organization:
Oncology Institute of Southern Switzerland
Class:
OTHER
Study ID:
IOSI-LND-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cristiana Sessa
Lead Sponsor Class:
OTHER
Responsible Party:
Cristiana Sessa
Responsible Party Title:
Prof
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Oncology Institute of Southern Switzerland
Old Name:
None
Old Organization:
None